By Donna Loyle, communications specialist, LIMR
Researchers are recruiting patients who’ve been diagnosed with stage 4 non-small cell lung cancer (NSCLC) for a phase II/III randomized study. The goal is to discern if maintenance chemotherapy and stereotactic body radiation therapy (SBRT) together work better than maintenance chemotherapy alone in treating patients with stage 4 NSCLC.
Eligible patients must have already received 4 cycles of first-line/induction chemotherapy and experienced a partial response or are in stable condition. The complete list of inclusion/exclusion criteria is on the Main Line Health Clinical Trials website listed below.
Patients are randomized into two treatment arms. Those in Arm 1 receive maintenance chemotherapy. Those in Arm 2 receive SBRT plus maintenance chemotherapy.
Principal investigators for study NRG LU002, which is available at Lankenau Medical Center, are Albert DeNittis, MD, and Paul Gilman, MD. For more information, visit https://www.mainlinehealth.org/research/clinical-trials/nrc-lu002.